Australia and New Zealand Fetal Bovine Serum Market by Origin (Australia Origin, New Zealand Origin, US Origin, Mexico Origin, and Brazil Origin) by Application (Biopharmaceuticals, Cell Culture, Human & Animal Vaccine Production, and Others), and End User (Biotechnology & Pharmaceutical Industry, Academic Institute, and Research Laboratory): Opportunity Analysis and Industry Forecast, 2021-2030
- ALL4676892
- 80 Pages
- September 2021
- Diagnostic and Biotech
Fetal bovine serum (FBS) is considered as an ideal medium growth supplement and is usually preferred over other types of sera available such as Horse Sea, goat sera, and others. High levels of nutrients and optimal combination of growth factors make it a suitable growth supplement for cell cultures. Further, the significantly lower content of antibodies compared to adult and newborn sera minimizes the risk of antibody cross reaction with cells in culture. FBS finds its application on several research purposes including cancer research, development of biopharmaceuticals, and other research purposes. In addition, sera are widely used as an additional growth supplement along with the culture media preparation made precisely for the growth, storage, maintenance, and transport of microorganisms and different types of cells. The array of various media available in research allows the culturing of cell types and microorganisms. The quality of FBS is determined chiefly at the blood collection site and the raw serum processing center. Appropriate collection is fundamental to maintaining the natural growth-promoting properties of fetal blood, thus achieving consistent and superior performance of the final Fetal Bovine Serum products.
Rise in research and development regarding the development of biopharmaceuticals fuel the growth of the fetal bovine serum industry. In addition, the constant expansion of biopharmaceutical research is anticipated to surge the demand of the production and supply chain for FBS market in near future. Moreover, increase in investments and funding for research interventions in both developed and developing countries drives the market growth. However, animal welfare and ethical & scientific concerns associated with the use of fetal bovine restrict the fetal bovine serum market growth. However, untapped potential of the emerging markets is anticipated to provide lucrative opportunities to the key players involved in the fetal bovine serum market.
By application, the market is categorized into biopharmaceuticals, cell culture media, human and animal vaccine production, and others. The cell culture segment was the highest contributor to the market in 2020 and is anticipated to maintain its dominance throughout the forecast period.
Other major factors that drive the overall FBS market in Australia and New Zealand include increased funding by the government agencies and rise in focus to develop biopharmaceuticals
The report provides a comprehensive analysis of the leading companies operating in the Australia and New Zealand market such as Atlas Biologicals, Biological Industries, Bio Techne, Biowest, GE Healthcare, HiMedia Laboratories Pvt. Ltd., Merck KGaA (Sigma Aldrich, Pan Biotech, Rocky Mountain Biologicals, and Thermo Fisher Scientific Inc. The other players in the value chain (not included in the report) include Takara Bio, Inc., Tissue Culture Biologicals, Caisson Laboratories, Inc., Cell Culture Technologies LLC and Biomol GmbH and Nucleus Biologics.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the Australia and New Zealand fetal bovine serum market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps to understand the products and end users of Australia and New Zealand fetal bovine serum used across the globe.
Key market players and their strategies have been analysed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Origin
• Australia Origin
• New Zealand Origin
• US Origin
• Mexico Origin
• Brazil Origin
By Application
• Biopharmaceuticals
• Cell Culture
• Human & Animal Vaccine Production
• Others
By End User
• Biotechnology & Pharmaceutical Industry
• Academic Institute
• Research Laboratory
KEY MARKET PLAYERS
• Atlas Biologicals
• Biological Industries
• Bio Techne
• Biowest
• GE Healthcare
• HiMedia Laboratories Pvt. Ltd.
• Merck KGaA (Sigma Aldrich)
• Pan Biotech
• Rocky Mountain Biologicals
• Thermo Fisher Scientific Inc.
1.1.REPORT DESCRIPTION
1.2.KEY MARKET SEGMENTS
1.3.KEY BENEFITS
1.4.RESEARCH METHODOLOGY
1.4.1.Primary research
1.4.2.Secondary research
1.4.3.Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1.CXO PERSPECTIVE
CHAPTER 3: MARKET LANDSCAPE
3.1.MARKET DEFINITION AND SCOPE
3.2.KEY FINDINGS
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.PORTER'S FIVE FORCES ANALYSIS
3.3.1.Bargaining power of suppliers
3.3.2.Threat of new entrants
3.3.3.Threat of substitutes
3.3.4.Competitive rivalry
3.3.5.Bargaining power among buyers
3.4.MARKET DYNAMICS
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5.COVID 19 IMPACT ANALYSIS
CHAPTER 4: AUSTRALIA AND NEW ZEALAND FETAL BOVINE SERUM MARKET BY ORIGIN
4.1.OVERVIEW
4.2. AUSTRALIA ORIGIN
4.2.1.Key market trends, growth factors andopportunities
4.2.2.Market size and forecast,
4.3. NEW ZEALAND ORIGIN
4.3.1.Key market trends, growth factors and opportunities
4.3.2.Market size and forecast,
4.4. US ORIGIN
4.4.1.Key market trends, growth factors and opportunities
4.4.2.Market size and forecast,
4.5. MEXICO ORIGIN
4.5.1.Key market trends, growth factors and opportunities
4.5.2.Market size and forecast,
4.6. BRAZIL ORIGIN
4.6.1.Key market trends, growth factors and opportunities
4.6.2.Market size and forecast,
CHAPTER 5: AUSTRALIA AND NEW ZEALAND FETAL BOVINE SERUM MARKET BY APPLICATION
5.1.OVERVIEW
5.2. BIOPHARMACEUTICALS
5.2.1.Key market trends, growth factors and opportunities
5.2.2.Market size and forecast,
5.3. CELL CULTURE
5.3.1.Key market trends, growth factors and opportunities
5.3.2.Market size and forecast,
5.4. HUMAN AND ANIMAL VACCINE PRODUCTION
5.4.1.Key market trends, growth factors and opportunities
5.4.2.Market size and forecast,
5.5. OTHERS
5.5.1.Key market trends, growth factors and opportunities
5.5.2.Market size and forecast,
CHAPTER 6: AUSTRALIA AND NEW ZEALAND FETAL BOVINE SERUM MARKET BY END USER
6.1.OVERVIEW
6.2. BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES
6.2.1.Key market trends, growth factors and opportunities
6.2.2.Market size and forecast,
6.2.3.Market size and forecast, by Origin
6.2.4.Market size and forecast, by Therapeutic Type
6.2.4.1. Gamma Irradiation
6.2.4.2. Heat Inactivation
6.2.4.3. Charcoal Stripped
6.2.4.4. Other
6.3. ACADEMIC INSTITUTE
6.3.1.Key market trends, growth factors and opportunities
6.3.2.Market size and forecast,
6.3.3.Market size and forecast, by Origin
6.3.4.Market size and forecast, by Therapeutic Type
6.3.4.1. Gamma Irradiation
6.3.4.2. Heat Inactivation
6.3.4.3. Charcoal Stripped
6.3.4.4. Other
6.4. RESEARCH LABORATORY
6.4.1.Key market trends, growth factors and opportunities
6.4.2.Market size and forecast,
6.4.3.Market size and forecast, by Origin
6.4.4.Market size and forecast, by Therapeutic Type
6.3.4.1. Gamma Irradiation
6.3.4.2. Heat Inactivation
6.3.4.3. Charcoal Stripped
6.3.4.4. Other
CHAPTER 7: COMPANY PROFILES
7.1. ATLAS BIOLOGICALS
7.1.1.Company overview
7.1.2.Key Executives
7.1.3.Company snapshot
7.1.4.Operating business segments
7.1.5.Product portfolio
7.1.6.Business performance
7.1.7.Key strategic moves and developments
7.2. BIOLOGICAL INDUSTRIES
7.2.1.Company overview
7.2.2.Key Executives
7.2.3.Company snapshot
7.2.4.Operating business segments
7.2.5.Product portfolio
7.2.6.Business performance
7.2.7.Key strategic moves and developments
7.3. BIO TECHNE
7.3.1.Company overview
7.3.2.Key Executives
7.3.3.Company snapshot
7.3.4.Operating business segments
7.3.5.Product portfolio
7.3.6.Business performance
7.3.7.Key strategic moves and developments
7.4. BIOWEST
7.4.1.Company overview
7.4.2.Key Executives
7.4.3.Company snapshot
7.4.4.Operating business segments
7.4.5.Product portfolio
7.4.6.Business performance
7.4.7.Key strategic moves and developments
7.5. GE HEALTHCARE
7.5.1.Company overview
7.5.2.Key Executives
7.5.3.Company snapshot
7.5.4.Operating business segments
7.5.5.Product portfolio
7.5.6.Business performance
7.5.7.Key strategic moves and developments
7.6. HIMEDIA LABORATORIES PVT. LTD.
7.6.1.Company overview
7.6.2.Key Executives
7.6.3.Company snapshot
7.6.4.Operating business segments
7.6.5.Product portfolio
7.6.6.Business performance
7.6.7.Key strategic moves and developments
7.7. MERCK KGAA (SIGMA ALDRICH)
7.7.1.Company overview
7.7.2.Key Executives
7.7.3.Company snapshot
7.7.4.Operating business segments
7.7.5.Product portfolio
7.7.6.Business performance
7.7.7.Key strategic moves and developments
7.8. PAN BIOTECH
7.8.1.Company overview
7.8.2.Key Executives
7.8.3.Company snapshot
7.8.4.Operating business segments
7.8.5.Product portfolio
7.8.6.Business performance
7.8.7.Key strategic moves and developments
7.9. ROCKY MOUNTAIN BIOLOGICALS
7.9.1.Company overview
7.9.2.Key Executives
7.9.3.Company snapshot
7.9.4.Operating business segments
7.9.5.Product portfolio
7.9.6.Business performance
7.9.7.Key strategic moves and developments
7.10. THERMO FISHER SCIENTIFIC INC.
7.10.1.Company overview
7.10.2.Key Executives
7.10.3.Company snapshot
7.10.4.Operating business segments
7.10.5.Product portfolio
7.10.6.Business performance
7.10.7.Key strategic moves and developments
TABLE 1. AUSTRALIA AND NEW ZEALAND FETAL BOVINE SERUM MARKET, BY ORIGIN 2020-2030 ($MILLION)
TABLE 2. AUSTRALIA AND NEW ZEALAND FETAL BOVINE SERUM MARKET, BY APPLICATION 2020-2030 ($MILLION)
TABLE 3. AUSTRALIA AND NEW ZEALAND FETAL BOVINE SERUM MARKET, BY END USER 2020-2030 ($MILLION)
TABLE 4.AUSTRALIA AND NEW ZEALAND FETAL BOVINE SERUM MARKET FOR , , 2020-2030 ($MILLION)
TABLE 5.ATLAS BIOLOGICALS: COMPANY SNAPSHOT
TABLE 6.ATLAS BIOLOGICALS: OPERATING SEGMENTS
TABLE 7.BIOLOGICAL INDUSTRIES: COMPANY SNAPSHOT
TABLE 8.BIOLOGICAL INDUSTRIES: OPERATING SEGMENTS
TABLE 9.BIO TECHNE: COMPANY SNAPSHOT
TABLE 10.BIO TECHNE: OPERATING SEGMENTS
TABLE 11.BIOWEST: COMPANY SNAPSHOT
TABLE 12.BIOWEST: OPERATING SEGMENTS
TABLE 13.GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 14.GE HEALTHCARE: OPERATING SEGMENTS
TABLE 15.HIMEDIA LABORATORIES PVT. LTD.: COMPANY SNAPSHOT
TABLE 16.HIMEDIA LABORATORIES PVT. LTD.: OPERATING SEGMENTS
TABLE 17.MERCK KGAA (SIGMA ALDRICH): COMPANY SNAPSHOT
TABLE 18.MERCK KGAA (SIGMA ALDRICH): OPERATING SEGMENTS
TABLE 19.PAN BIOTECH: COMPANY SNAPSHOT
TABLE 20.PAN BIOTECH: OPERATING SEGMENTS
TABLE 21.ROCKY MOUNTAIN BIOLOGICALS: COMPANY SNAPSHOT
TABLE 22.ROCKY MOUNTAIN BIOLOGICALS: OPERATING SEGMENTS
TABLE 23.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 24.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
Similar Reports
Complete report $6,100. DataPack (test volumes, sales forecasts, supplier shares) $3,950.
Summary
This comprehensive report contains 409 pages, 35 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the UK coagulation testing market duri...
- Publish Date: February 7, 2017
- $750
Complete report $9,600. DataPack (test volumes, sales forecasts, supplier shares) $6,200.
Summary
This comprehensive report contains 424 pages, 37 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the US coagulation testing market during the...
- Publish Date: February 7, 2017
- $750
This new report from VPGMarketResearch.com provides strategic assessments of major blood banking product suppliers and emerging market entrants. The report presents analyses of major current and emerging suppliers in terms of their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.
Con...
- Publish Date: February 7, 2017
- $750
